title: [Role of classical oral glucose-lowering medications in current treatment].
abstract: Classical oral glucose were discovered in the mid twentieth century. Despite the time elapsed since then and the lack of large studies to support the use of some of these drugs, they continue to be employed, are indicated in all clinical practice guidelines and consensus documents and, overall, remain among the most widely prescribed drugs in the national health system. The main arguments for their continued use are their widespread and prolonged prescription, their effectiveness, and cost. Their main disadvantages have always been and continue to be their adverse gastrointestinal effects, weight gain, the risk of hypoglycemia and other adverse effects, which have encouraged the development of new glucose-lowering drugs with an improved pharmacological profile that would cover the various mechanisms of hyperglycemia. Currently, deep knowledge of glucose-lowering drugs is required in the patient-centered management of diabetes. Furthermore, this knowledge should be adapted to each individual patient to acquire the experience necessary to achieve effective metabolic control, delay the development of chronic complications, and improve the quality of life and life expectancy of patients with diabetes.
authors.affiliation: Medicina de Familia, Centro de Salud San Roque, Badajoz, España; Gerencia del Área de Salud de Badajoz-Zafra Llerena, Badajoz, España; Grupo de Trabajo de Diabetes de SEMERGEN. Electronic address: fcbzafra@gmail.com.
authors.forename: F C
authors.initials: FC
authors.lastname: Carramiñana Barrera
mesh_terms: D001786:Blood Glucose / Q000187:drug effects*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008017:Life Expectancy; D018802:Patient-Centered Care / Q000379:methods; D017410:Practice Guidelines as Topic; D011788:Quality of Life
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents
keywords: Cost; Coste; Diabetes mellitus tipo 2; Effectiveness; Eficacia; Hipoglucemia; Hipoglucemiantes orales; Hypoglycemia; Manejo centrado en el paciente; Oral glucose-lowering drugs; Patient-centered management; Type 2 diabetes mellitus